USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
THERATARGET
Address:
615 Arapeen Drive, Suite 302-Y
Salt Lake City, UT 84108-1289
Phone:
N/A
URL:
N/A
EIN:
126382449
DUNS:
828787379
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $348,304.00 3
STTR Phase II $995,235.00 1

Award List:

Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Hamid Ghandehari – 801-587-1566
Research Institution:
University Of Utah
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of a polymeric delivery system that will deliver two anticancer drugs with diverse mechanisms of action simultaneously into ovarian cancer cells. The delivery… More

Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$148,304.00
Agency:
HHS
Principal Investigator:
Jindrich H. Kopecek – 801-581-7211
Research Institution:
UNIVERSITY OF UTAH
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of targeted, backbone degradable, long-circulating polymer conjugates containing two anticancer drugs per macromolecule. The polymeric carrier will be… More

In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Hamid Ghandehari – 801-587-1566
Research Institution:
UNIVERSITY OF UTAH
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This Phase I proposal addresses the significant need for improved treatment options for patients with liver cancer, the fifth highest incidence of cance in the world. Because of the lack of symptoms, hepatocellular carcinoma (HCC) is detected at advanced stages… More

Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

Award Year / Program / Phase:
2014 / STTR / Phase II
Award Amount:
$995,235.00
Agency:
HHS
Principal Investigator:
Jindrich H. Kopecek – 801-581-7211
Research Institution:
UNIVERSITY OF UTAH
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents, gemcitabine and paclitaxel. Based on the successful results of the STTR Phase I award, this Phase II proposal details the… More